{"id":"placebo-citalopram","safety":{"commonSideEffects":[{"rate":"15-21%","effect":"Nausea"},{"rate":"13-24%","effect":"Headache"},{"rate":"10-18%","effect":"Somnolence"},{"rate":"10-15%","effect":"Insomnia"},{"rate":"9-16%","effect":"Dry mouth"},{"rate":"8-15%","effect":"Diarrhea"},{"rate":"10-15%","effect":"Sexual dysfunction"},{"rate":"5-11%","effect":"Tremor"}]},"_chembl":{"chemblId":"CHEMBL1200781","moleculeType":"Small molecule","molecularWeight":"405.31"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Citalopram selectively inhibits the reuptake of serotonin at the serotonin transporter (SERT), leading to increased serotonin concentration in the synaptic cleft. This enhanced serotonergic neurotransmission is thought to improve mood and reduce symptoms of depression and anxiety. The placebo component in this study design serves as a control to assess the true pharmacological effect of citalopram versus placebo response.","oneSentence":"Citalopram is a selective serotonin reuptake inhibitor (SSRI) that increases serotonin availability in the brain by blocking its reuptake at the presynaptic neuron.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:37:00.065Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Major depressive disorder"},{"name":"Generalized anxiety disorder"},{"name":"Panic disorder"},{"name":"Obsessive-compulsive disorder"}]},"trialDetails":[{"nctId":"NCT04497168","phase":"PHASE2","title":"Citalopram as a Posterior Cortical Protective Therapy in Parkinson Disease","status":"COMPLETED","sponsor":"University of Michigan","startDate":"2021-04-01","conditions":"Parkinson Disease","enrollment":58},{"nctId":"NCT05901571","phase":"NA","title":"Acupuncture and Escitalopram for Treating Major Depression Clinical Study","status":"NOT_YET_RECRUITING","sponsor":"Shanghai 7th People's Hospital","startDate":"2026-11","conditions":"Depressive Disorder, Major","enrollment":216},{"nctId":"NCT07139834","phase":"PHASE1","title":"Pattern Separation in Major Depressive Disorder","status":"NOT_YET_RECRUITING","sponsor":"Jeffrey Miller","startDate":"2026-04","conditions":"Major Depressive Disorder (MDD)","enrollment":30},{"nctId":"NCT05017311","phase":"PHASE4","title":"Optimized Predictive Treatment In Medications for Unipolar Major Depression (OPTIMUM-D)","status":"RECRUITING","sponsor":"Nova Scotia Health Authority","startDate":"2023-01-20","conditions":"Major Depressive Disorder","enrollment":400},{"nctId":"NCT06826326","phase":"PHASE2","title":"Neuroimaging of Escitalopram in Autism Spectrum Disorder","status":"ENROLLING_BY_INVITATION","sponsor":"Kathryn Unruh","startDate":"2025-04-28","conditions":"Autism Spectrum Disorder","enrollment":5},{"nctId":"NCT06216535","phase":"PHASE2","title":"Escitalopram in Asthma Patients With Frequent Exacerbation","status":"RECRUITING","sponsor":"University of Texas Southwestern Medical Center","startDate":"2025-05-19","conditions":"Asthma","enrollment":105},{"nctId":"NCT07331987","phase":"NA","title":"Efficacy and Safety of Probiotics for Anxiety Depression","status":"NOT_YET_RECRUITING","sponsor":"Moon (Guangzhou) Biotechnology Co., Ltd.","startDate":"2026-03-01","conditions":"Anxiety Depression","enrollment":60},{"nctId":"NCT06965569","phase":"PHASE1","title":"Multiple Ascending Dose Phase 1 Study of ALA-3000","status":"COMPLETED","sponsor":"Alar Pharmaceuticals Inc.","startDate":"2025-04-21","conditions":"Treatment Resistant Depression","enrollment":37},{"nctId":"NCT06433635","phase":"PHASE4","title":"Sequential Multiple Assignment Randomized Trial for Bipolar Depression","status":"ACTIVE_NOT_RECRUITING","sponsor":"Massachusetts General Hospital","startDate":"2024-10-01","conditions":"Bipolar I Disorder, Depression","enrollment":2726},{"nctId":"NCT05289830","phase":"PHASE2","title":"Escitalopram to Placebo in Patients With Localized Pancreatic Cancer","status":"TERMINATED","sponsor":"Case Comprehensive Cancer Center","startDate":"2022-08-05","conditions":"Pancreatic Ductal Adenocarcinoma, Periampullary Cancer","enrollment":4},{"nctId":"NCT06692361","phase":"NA","title":"Assessment of the Efficacy and Safety of Fecal Microbiota Transplantation (FMT) in Patients With Major Depressive Disorder","status":"RECRUITING","sponsor":"Gang Wang","startDate":"2025-01-01","conditions":"Major Depressive Disorder (MDD), Depression - Major Depressive Disorder","enrollment":214},{"nctId":"NCT03843463","phase":"PHASE2","title":"Escitalopram and Language Intervention for Subacute Aphasia","status":"RECRUITING","sponsor":"Johns Hopkins University","startDate":"2021-07-18","conditions":"Aphasia, Stroke","enrollment":88},{"nctId":"NCT04846829","phase":"EARLY_PHASE1","title":"Effects of Intravenous (IV) Citalopram Hydrochloride During Transcranial Magnetic Stimulation in Major Depressive Disorder (MDD)","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of California, Los Angeles","startDate":"2017-04-24","conditions":"Major Depressive Disorder","enrollment":30},{"nctId":"NCT06591091","phase":"PHASE2","title":"Clemastine for Improving White Matter and Boosting Antidepressant Response in Late-life Depression","status":"NOT_YET_RECRUITING","sponsor":"University of Illinois at Chicago","startDate":"2025-09","conditions":"Depression","enrollment":80},{"nctId":"NCT06001021","phase":"NA","title":"Cognitive Behavioral Couple Therapy for Perinatal Distress","status":"COMPLETED","sponsor":"Sameera Shafiq","startDate":"2023-08-15","conditions":"Perinatal Depression, Perinatal Anxiety","enrollment":96},{"nctId":"NCT07120880","phase":"PHASE3","title":"Efficacy of Chronotherapeutic Combination for Major Depressive Episode With Insomnia","status":"NOT_YET_RECRUITING","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2025-09","conditions":"Major Depressive Disorder (MDD) With Insomnia","enrollment":184},{"nctId":"NCT03527043","phase":"PHASE2","title":"Impact of Escitalopram on Sperm DNA Fragmentation","status":"TERMINATED","sponsor":"Weill Medical College of Cornell University","startDate":"2017-10-01","conditions":"Sperm DNA Fragmentation, Infertility, Male","enrollment":75},{"nctId":"NCT06192589","phase":"PHASE1","title":"Clinical Study to Evaluate Cannabidiol Liver Enzyme Elevations and Drug Interactions","status":"COMPLETED","sponsor":"Food and Drug Administration (FDA)","startDate":"2024-02-08","conditions":"Cannabidiol, Drug Induced Liver Injury, Drug Interaction","enrollment":241},{"nctId":"NCT07074652","phase":"NA","title":"The Effect of SSRIs on Threat of Shock Potentiated Neural Circuitry","status":"COMPLETED","sponsor":"UCLH/UCL Joint Research Office","startDate":"2017-12-01","conditions":"Anxiety","enrollment":145},{"nctId":"NCT06949644","phase":"NA","title":"Pupillometry in Delayed Sleep Wake Phase Disorder","status":"NOT_YET_RECRUITING","sponsor":"Northwestern University","startDate":"2025-08-01","conditions":"Delayed Sleep-Wake Phase Disorder","enrollment":220},{"nctId":"NCT04344678","phase":"NA","title":"The Phosphodiesterase 5 Inhibitor Sildenafil as an Adjunct to Antidepressants in Major Depressive Disorder Patients","status":"WITHDRAWN","sponsor":"Sadat City University","startDate":"2020-01-01","conditions":"Major Depressive Disorder","enrollment":""},{"nctId":"NCT04410341","phase":"PHASE1, PHASE2","title":"The DPP-4 Inhibitor Vildagliptin as Adjunct in Major Depressive Disorder Patients","status":"WITHDRAWN","sponsor":"Sadat City University","startDate":"2020-05-01","conditions":"Major Depressive Disorder","enrollment":""},{"nctId":"NCT03887624","phase":"EARLY_PHASE1","title":"Investigate the Clinical Responses of Ethosuximide in Patients With Treatment-Resistant Depression.","status":"COMPLETED","sponsor":"Zhejiang University","startDate":"2019-05-21","conditions":"Depressive Disorder, Treatment-Resistant","enrollment":16},{"nctId":"NCT05004987","phase":"PHASE4","title":"Aβ Dynamics in LLMD","status":"RECRUITING","sponsor":"NYU Langone Health","startDate":"2022-02-04","conditions":"Alzheimer Disease, Major Depressive Disorder","enrollment":60},{"nctId":"NCT05536414","phase":"PHASE2","title":"Trial of Centanafadine Efficacy and Safety as Monotherapy or as Adjunct to SSRI in Adults With Major Depressive Disorder","status":"COMPLETED","sponsor":"Otsuka Pharmaceutical Development & Commercialization, Inc.","startDate":"2022-09-12","conditions":"Major Depressive Disorder","enrollment":337},{"nctId":"NCT05470465","phase":"PHASE1","title":"Effect of Selective Serotonin Reuptake Inhibitors (SSRIs) and an Opioid on Ventilation","status":"COMPLETED","sponsor":"Food and Drug Administration (FDA)","startDate":"2022-09-01","conditions":"Hypercapnia, Ventilatory Depression","enrollment":27},{"nctId":"NCT00958633","phase":"PHASE3","title":"Mood Stabilizer (MS)+ Antidepressant vs MS + Placebo in Maintenance of Bipolar Disorder.","status":"TERMINATED","sponsor":"University of British Columbia","startDate":"2010-11","conditions":"Bipolar I Disorder","enrollment":237},{"nctId":"NCT02417064","phase":"PHASE3","title":"A Study to Evaluate the Efficacy, Safety, and Tolerability of Fixed Doses of Intranasal Esketamine Plus an Oral Antidepressant in Adult Participants With Treatment-resistant Depression","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2015-08-10","conditions":"Treatment-resistant Depression","enrollment":346},{"nctId":"NCT03434041","phase":"PHASE3","title":"A Study to Evaluate the Efficacy, Pharmacokinetics, Safety and Tolerability of Flexible Doses of Intranasal Esketamine Plus an Oral Antidepressant in Adult Participants With Treatment-resistant Depression","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2018-05-25","conditions":"Depressive Disorder, Treatment-Resistant","enrollment":252},{"nctId":"NCT02493868","phase":"PHASE3","title":"A Study of Intranasal Esketamine Plus an Oral Antidepressant for Relapse Prevention in Adult Participants With Treatment-resistant Depression","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2015-10-01","conditions":"Depressive Disorder, Treatment-Resistant","enrollment":719},{"nctId":"NCT02418585","phase":"PHASE3","title":"A Study to Evaluate the Efficacy, Safety, and Tolerability of Flexible Doses of Intranasal Esketamine Plus an Oral Antidepressant in Adult Participants With Treatment-resistant Depression","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2015-08-07","conditions":"Treatment-resistant Depression","enrollment":236},{"nctId":"NCT02422186","phase":"PHASE3","title":"A Study to Evaluate the Efficacy, Safety, and Tolerability of Intranasal Esketamine Plus an Oral Antidepressant in Elderly Participants With Treatment-resistant Depression","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2015-08-20","conditions":"Depressive Disorder, Treatment-Resistant","enrollment":139},{"nctId":"NCT03321526","phase":"PHASE2","title":"A Study to Compare the Efficacy, Safety, and Tolerability of JNJ-42847922 Versus Quetiapine Extended-Release as Adjunctive Therapy to Antidepressants in Adult Participants With Major Depressive Disorder Who Have Responded Inadequately to Antidepressant Therapy","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2017-12-12","conditions":"Depressive Disorder, Major","enrollment":107},{"nctId":"NCT04951609","phase":"PHASE1","title":"A Study of Seltorexant as Adjunctive Therapy to Antidepressants in Adolescents With Major Depressive Disorder Who Have an Inadequate Response to Selective Serotonin Reuptake Inhibitor (SSRI) and Psychotherapy","status":"TERMINATED","sponsor":"Janssen Research & Development, LLC","startDate":"2021-09-02","conditions":"Depressive Disorder, Major","enrollment":31},{"nctId":"NCT03852160","phase":"PHASE3","title":"A Study of Esketamine Nasal Spray Plus a New Standard-of-care Oral Antidepressant or Placebo Nasal Spray Plus a New Standard-of-care Oral Antidepressant in Adult and Elderly Participants With Treatment-resistant Depression","status":"WITHDRAWN","sponsor":"Janssen-Cilag International NV","startDate":"2019-12-01","conditions":"Depressive Disorder, Treatment-Resistant","enrollment":""},{"nctId":"NCT06828887","phase":"PHASE2","title":"Dose-Finding Clinical Trial to Evaluate the Efficacy and Safety of LV232 Capsules in the Treatment of MDD","status":"RECRUITING","sponsor":"Vigonvita Life Sciences","startDate":"2025-04-03","conditions":"MDD","enrollment":400},{"nctId":"NCT03920410","phase":"NA","title":"Effect of Serotonergic Stimulation on the Gut-brain Axis","status":"ACTIVE_NOT_RECRUITING","sponsor":"Örebro University, Sweden","startDate":"2019-04-24","conditions":"Healthy, Irritable Bowel Syndrome","enrollment":58},{"nctId":"NCT03128021","phase":"PHASE4","title":"Neural Mechanisms of Monoaminergic Engagement in Late-life Depression Treatment Response (NEMO)","status":"COMPLETED","sponsor":"Howard Aizenstein","startDate":"2017-05-24","conditions":"Major Depressive Disorder","enrollment":57},{"nctId":"NCT03854578","phase":"PHASE1","title":"A Study in People With Depression to Test the Effects of BI 1358894 on Parts of the Brain That Are Involved in Emotions","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2019-03-12","conditions":"Depressive Disorder, Major","enrollment":73},{"nctId":"NCT06412315","phase":"NA","title":"7T Amygdala and Citalopram Study","status":"RECRUITING","sponsor":"University of Oxford","startDate":"2025-02-13","conditions":"Emotional Processing, Cognition, Mood Disorders","enrollment":50},{"nctId":"NCT01778686","phase":"NA","title":"Evaluation of [11C]Cimbi-36 as an Agonist PET Radioligand for Imaging of 5-HT2A Receptors","status":"COMPLETED","sponsor":"Gitte Moos Knudsen","startDate":"2013-01","conditions":"Healthy","enrollment":24},{"nctId":"NCT03108846","phase":"PHASE3","title":"Escitalopram for Agitation in Alzheimer's Disease","status":"ACTIVE_NOT_RECRUITING","sponsor":"JHSPH Center for Clinical Trials","startDate":"2018-01-03","conditions":"Dementia","enrollment":187},{"nctId":"NCT06758167","phase":"NA","title":"RCT Study on the Therapeutic Effect of Escitalopram Loaded With XingpiJieyu Formula on Resting State EEG Energy Abnormalities in Severe Liver Depression and Spleen Deficiency Type MDD","status":"COMPLETED","sponsor":"Peking University Sixth Hospital","startDate":"2020-11-14","conditions":"Major Depression","enrollment":150},{"nctId":"NCT04336228","phase":"PHASE4","title":"The Role of Serotonin in Compulsive Behavior in Humans: Underlying Brain Mechanisms","status":"ACTIVE_NOT_RECRUITING","sponsor":"Rigshospitalet, Denmark","startDate":"2020-04-01","conditions":"Obsessive-Compulsive Disorder/High Compulsive Individuals, Healthy Individuals","enrollment":46},{"nctId":"NCT04301271","phase":"PHASE2","title":"Simvastatin add-on Treatment to Standard Antidepressant Therapy in Patients With Comorbid Obesity and Major Depression","status":"COMPLETED","sponsor":"Charite University, Berlin, Germany","startDate":"2020-08-13","conditions":"Depressive Disorder, Major, Obesity","enrollment":161},{"nctId":"NCT06696482","phase":"PHASE1, PHASE2","title":"Effort and Antidepressant Study Test","status":"NOT_YET_RECRUITING","sponsor":"University of Oxford","startDate":"2025-01","conditions":"Effort Based Decision Making, Prosocial Behavior, Apathy","enrollment":50},{"nctId":"NCT03429075","phase":"PHASE2","title":"Psilocybin vs Escitalopram for Major Depressive Disorder: Comparative Mechanisms","status":"COMPLETED","sponsor":"Imperial College London","startDate":"2019-01-07","conditions":"Depressive Disorder, Major","enrollment":59},{"nctId":"NCT00200902","phase":"PHASE4","title":"Evaluation of Depression Symptoms and Brain Activity Associated With Response to Treatment of Depression","status":"COMPLETED","sponsor":"University of California, Los Angeles","startDate":"2005-08","conditions":"Depression","enrollment":88},{"nctId":"NCT05627154","phase":"NA","title":"Combined Antidepressant and Behavioural Intervention","status":"COMPLETED","sponsor":"University of Oxford","startDate":"2021-05-28","conditions":"Low Mood, Depression, Anxiety","enrollment":134},{"nctId":"NCT02620150","phase":"PHASE4","title":"SSRI Effects on Depression and Immunity in HIV/AIDS","status":"COMPLETED","sponsor":"University of Pennsylvania","startDate":"2017-02-16","conditions":"Depression, HIV, AIDS","enrollment":108},{"nctId":"NCT01479829","phase":"PHASE4","title":"Cyclooxygenase-2-Inhibitor Combination Treatment for Bipolar Depression","status":"COMPLETED","sponsor":"Loyola University","startDate":"2011-03-23","conditions":"Bipolar Depression","enrollment":100},{"nctId":"NCT01032083","phase":"PHASE4","title":"Antidepressant Controlled Trial for Negative Symptoms in Schizophrenia","status":"COMPLETED","sponsor":"Imperial College London","startDate":"2011-07","conditions":"Schizophrenia","enrollment":62},{"nctId":"NCT06266715","phase":"NA","title":"Improvement of Depression With Use of ATP","status":"RECRUITING","sponsor":"Nanfang Hospital, Southern Medical University","startDate":"2024-03-04","conditions":"Depression","enrollment":120},{"nctId":"NCT06212284","phase":"NA","title":"Serotonin, Anxiety and Visceral Sensation","status":"COMPLETED","sponsor":"University of Sussex","startDate":"2018-02-18","conditions":"Healthy","enrollment":31},{"nctId":"NCT04975724","phase":"PHASE4","title":"Safety of Liposom With Citalopram in Elderly Patients With Major Depressive Disorder","status":"UNKNOWN","sponsor":"Fidia Farmaceutici s.p.a.","startDate":"2019-04-18","conditions":"Major Depressive Disorder","enrollment":150},{"nctId":"NCT04476030","phase":"PHASE3","title":"A Comparative Study of Sage-217 Plus an Antidepressant (ADT) Versus Placebo Plus an ADT in Adults With Major Depressive Disorder","status":"COMPLETED","sponsor":"Biogen","startDate":"2020-11-09","conditions":"Depressive Disorder, Major","enrollment":440},{"nctId":"NCT05818735","phase":"NA","title":"Effect of Electroacupuncture on Treating the First-episode Depression","status":"RECRUITING","sponsor":"Shanghai Municipal Hospital of Traditional Chinese Medicine","startDate":"2023-12-01","conditions":"Depression","enrollment":204},{"nctId":"NCT04239339","phase":"PHASE4","title":"Serotonergic Modulation of Cognition, Emotion and Brain Activation in Healthy Volunteers","status":"COMPLETED","sponsor":"Rigshospitalet, Denmark","startDate":"2020-04-28","conditions":"Healthy","enrollment":66},{"nctId":"NCT03538691","phase":"PHASE3","title":"A Trial to Evaluate the Efficacy, Safety & Tolerability of Brexpiprazole in the Maintenance Treatment of Adults With Major Depressive Disorder","status":"COMPLETED","sponsor":"Otsuka Pharmaceutical Development & Commercialization, Inc.","startDate":"2018-07-13","conditions":"Major Depressive Disorder","enrollment":1149},{"nctId":"NCT02389465","phase":"PHASE4","title":"Stress and Inflammation in Late-Life Depression","status":"COMPLETED","sponsor":"University of Pennsylvania","startDate":"2014-08","conditions":"Depression, Inflammation","enrollment":119},{"nctId":"NCT00536172","phase":"PHASE4","title":"Evaluating the Effectiveness of Escitalopram to Prevent Depression in Head and Neck Cancer Patients Receiving Treatment","status":"COMPLETED","sponsor":"University of Nebraska","startDate":"2007-12-01","conditions":"Depression","enrollment":160},{"nctId":"NCT06017037","phase":"PHASE1, PHASE2","title":"REward Processing And Citalopram Study","status":"UNKNOWN","sponsor":"University of Oxford","startDate":"2023-05-19","conditions":"Anhedonia","enrollment":40},{"nctId":"NCT05957094","phase":"NA","title":"Human Cerebral Blood Flow and Serotonin","status":"UNKNOWN","sponsor":"University of British Columbia","startDate":"2023-08","conditions":"Depression, Serotonin Deficiency","enrollment":15},{"nctId":"NCT02058693","phase":"PHASE4","title":"Adjunctive Mixed Salts Amphetamine for Depressed Adults With Incomplete Response to Current Antidepressant Therapy","status":"COMPLETED","sponsor":"Rush University Medical Center","startDate":"2010-12","conditions":"Major Depressive Disorder","enrollment":41},{"nctId":"NCT05850572","phase":"NA","title":"A Study of the Efficacy of Fecal Microbiota Transplantation(FMT) in the Treatment of Depression","status":"NOT_YET_RECRUITING","sponsor":"First Affiliated Hospital Xi'an Jiaotong University","startDate":"2023-07","conditions":"Depression","enrollment":100},{"nctId":"NCT03652870","phase":"PHASE3","title":"Antidepressants Trial in Parkinson's Disease","status":"COMPLETED","sponsor":"University College, London","startDate":"2021-03-05","conditions":"Depression, Parkinson Disease","enrollment":52},{"nctId":"NCT05840692","phase":"PHASE4","title":"The Effect of Escitalopram in PCOS","status":"COMPLETED","sponsor":"Odense University Hospital","startDate":"2013-08","conditions":"Polycystic Ovary Syndrome","enrollment":40},{"nctId":"NCT05480878","phase":"PHASE3","title":"Role of Nitazoxanide and Escitalopram in Patients With Rheumatoid Arthritis","status":"COMPLETED","sponsor":"Tanta University","startDate":"2022-12-02","conditions":"Rheumatoid Arthritis","enrollment":90},{"nctId":"NCT04836533","phase":"PHASE1","title":"Enhancing Processing Speed and Executive Functioning in Depressed Older Adults With Computerized Cognitive Training","status":"WITHDRAWN","sponsor":"Queens College, The City University of New York","startDate":"2023-01-31","conditions":"Depression in Old Age, Depression","enrollment":""},{"nctId":"NCT05735756","phase":"PHASE4","title":"Effect of Citalopram on Chest Pain in Patients With Functional Chest Pain","status":"TERMINATED","sponsor":"Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)","startDate":"2022-01-17","conditions":"Functional Chest Pain","enrollment":1},{"nctId":"NCT05730062","phase":"PHASE1","title":"Influence of Oxycodone on Individuals Taking an SSRI","status":"UNKNOWN","sponsor":"Leiden University Medical Center","startDate":"2023-03-15","conditions":"Opioid Induced Respiratory Depression, Depressive Disorder, Anxiety Disorders","enrollment":55},{"nctId":"NCT02623205","phase":"PHASE4","title":"Advancing Personalized Antidepressant Treatment Using PET/MRI","status":"COMPLETED","sponsor":"Stony Brook University","startDate":"2015-05","conditions":"Depression","enrollment":85},{"nctId":"NCT01667744","phase":"PHASE1, PHASE2","title":"Citalopram for Sx/Util in Acute Coronary Syndrome Patients","status":"WITHDRAWN","sponsor":"Henry Ford Health System","startDate":"2016-01-01","conditions":"Acute Coronary Syndrome","enrollment":""},{"nctId":"NCT03924323","phase":"PHASE4","title":"A Study of Escitalopram in the Treatment of Children and Adolescents With Generalized Anxiety Disorder","status":"COMPLETED","sponsor":"AbbVie","startDate":"2019-05-30","conditions":"Anxiety Disorders,Generalized Anxiety Disorder","enrollment":273},{"nctId":"NCT03516604","phase":"PHASE1","title":"PF-04995274 and Emotional Processing in Un-medicated Depression","status":"COMPLETED","sponsor":"University of Oxford","startDate":"2018-05-16","conditions":"Depression, Unipolar","enrollment":90},{"nctId":"NCT02674529","phase":"PHASE2, PHASE3","title":"Study of Neural Responses Induced by Antidepressant Effects","status":"COMPLETED","sponsor":"Marta Peciña, MD PhD","startDate":"2016-09","conditions":"Major Depressive Disorder","enrollment":60},{"nctId":"NCT04069819","phase":"NA","title":"The Phosphodiesterase-3 Inhibitor Cilostazol as an Adjunctive to Antidepressants in Patients With Major Depressive Disorder.","status":"COMPLETED","sponsor":"Sadat City University","startDate":"2019-08-01","conditions":"Major Depressive Disorder","enrollment":80},{"nctId":"NCT05271084","phase":"PHASE1, PHASE2","title":"Pentoxifylline as an Adjunct to Citalopram in Adult Patients With Major Depressive Disorder","status":"COMPLETED","sponsor":"Hawler Medical University","startDate":"2021-11-10","conditions":"Major Depressive Disorder","enrollment":100},{"nctId":"NCT02532660","phase":"PHASE3","title":"Study to Evaluate the Efficacy of LABCAT TCJUSS in Patients With Depressive Episode","status":"TERMINATED","sponsor":"Laboratório Catarinense SA","startDate":"2018-07-02","conditions":"Depression","enrollment":111},{"nctId":"NCT03812588","phase":"PHASE4","title":"Contact: Developing New Clinical Management Strategies","status":"COMPLETED","sponsor":"New York State Psychiatric Institute","startDate":"2019-01-30","conditions":"Major Depressive Disorder","enrollment":29},{"nctId":"NCT04145076","phase":"NA","title":"Brain Response to Serotonergic Medications in ASD","status":"UNKNOWN","sponsor":"King's College London","startDate":"2014-12-15","conditions":"Autism Spectrum Disorder","enrollment":100},{"nctId":"NCT04965272","phase":"PHASE2","title":"A Study To Assess Adverse Events and Change in Disease Activity With Oral Cariprazine When Added to Antidepressant Therapies (ADTs) Compared to Placebo in Adult Participants With Generalized Anxiety Disorder (GAD) Who Have Had an Inadequate Response to ADTs Alone","status":"WITHDRAWN","sponsor":"AbbVie","startDate":"2021-08-18","conditions":"Generalized Anxiety Disorder","enrollment":""},{"nctId":"NCT01111552","phase":"PHASE3","title":"Study to Evaluate the Efficacy, Safety and Tolerability of an Oral Aripiprazole/Escitalopram Combination Therapy in Participants With Major Depressive Disorder (MDD)","status":"TERMINATED","sponsor":"Otsuka Pharmaceutical Development & Commercialization, Inc.","startDate":"2010-07-29","conditions":"Major Depressive Disorder (MDD)","enrollment":237},{"nctId":"NCT02332291","phase":"PHASE4","title":"Connectivity Affecting the Antidepressant REsponse Study","status":"COMPLETED","sponsor":"Vanderbilt University Medical Center","startDate":"2015-04","conditions":"Major Depressive Disorder","enrollment":95},{"nctId":"NCT03388164","phase":"PHASE2","title":"Adherence to Antidepressant Treatment in Subjects With Depression","status":"TERMINATED","sponsor":"Laureate Institute for Brain Research, Inc.","startDate":"2018-01-01","conditions":"Depression","enrollment":23},{"nctId":"NCT05041582","phase":"PHASE3","title":"SSRIs and TDCS Enhance Post-stroke Motor Recovery","status":"UNKNOWN","sponsor":"Chih-Wei Tang","startDate":"2021-09-01","conditions":"Stroke, Motor","enrollment":80},{"nctId":"NCT04221256","phase":"PHASE1, PHASE2","title":"Dose-finding Study of Selective Serotonin Reuptake Inhibitors to Enhance Neuroplasticity","status":"WITHDRAWN","sponsor":"Burke Medical Research Institute","startDate":"2020-03-11","conditions":"Stroke, Ischemic","enrollment":""},{"nctId":"NCT00905424","phase":"PHASE2","title":"Exploratory Study of SPD489 in Adults With Major Depressive Disorder (MDD) as Augmentation Therapy to an Antidepressant","status":"COMPLETED","sponsor":"Shire","startDate":"2009-07-30","conditions":"Major Depressive Disorder","enrollment":246},{"nctId":"NCT02516332","phase":"NA","title":"Exercise and Pharmacotherapy for Anxiety in Cardiac Patients","status":"COMPLETED","sponsor":"Duke University","startDate":"2015-12","conditions":"Anxiety, Cardiovascular Disease","enrollment":128},{"nctId":"NCT01436162","phase":"PHASE3","title":"Efficacy and Safety Study of SPD489 in Combination With an Antidepressant in the Treatment of Adults With Major Depressive Disorder","status":"COMPLETED","sponsor":"Shire","startDate":"2011-10-19","conditions":"Major Depressive Disorder","enrollment":1105},{"nctId":"NCT01436149","phase":"PHASE3","title":"Efficacy and Safety Study of SPD489 in Combination With an Antidepressant in the Treatment of Adults With Major Depressive Disorder","status":"COMPLETED","sponsor":"Shire","startDate":"2011-10-27","conditions":"Major Depressive Disorder","enrollment":1262},{"nctId":"NCT04097288","phase":"PHASE1","title":"Effects of Single Dose Citalopram and Reboxetine on Urethral and Anal Closure Function on Healthy Female Subjects","status":"COMPLETED","sponsor":"University Hospital Bispebjerg and Frederiksberg","startDate":"2019-09-17","conditions":"Stress Urinary Incontinence, Fecal Incontinence","enrollment":24},{"nctId":"NCT02092974","phase":"PHASE1","title":"Mechanism of tDCS-induced Learning Enhancement - the Role of Serotonin","status":"COMPLETED","sponsor":"Charite University, Berlin, Germany","startDate":"2014-04","conditions":"Healthy Young and Older Adults","enrollment":40},{"nctId":"NCT03912974","phase":"PHASE1","title":"Effects of SERT Inhibition on the Subjective Response to Psilocybin in Healthy Subjects","status":"COMPLETED","sponsor":"University Hospital, Basel, Switzerland","startDate":"2019-07-04","conditions":"Healthy","enrollment":27},{"nctId":"NCT02818751","phase":"NA","title":"Neurofunctional Predictors of Escitalopram Treatment Response in Adolescents With Anxiety","status":"COMPLETED","sponsor":"University of Cincinnati","startDate":"2015-05","conditions":"Anxiety","enrollment":84},{"nctId":"NCT01535573","phase":"PHASE2","title":"Citalopram for Cocaine Dependence","status":"COMPLETED","sponsor":"Joy Schmitz","startDate":"2010-12","conditions":"Cocaine Dependence","enrollment":108},{"nctId":"NCT00166296","phase":"PHASE2","title":"Efficacy and Safety of Escitalopram for Prevention of Depression Induced by Peg-Interferon in Hepatitis C Patients","status":"COMPLETED","sponsor":"Germans Trias i Pujol Hospital","startDate":"2005-03","conditions":"Major Depressive Disorder, Hepatitis C, Chronic","enrollment":133},{"nctId":"NCT01931202","phase":"NA","title":"Mechanisms of Antidepressant Non-Response in Late-Life Depression","status":"COMPLETED","sponsor":"New York State Psychiatric Institute","startDate":"2014-02-19","conditions":"Major Depressive Disorder","enrollment":138},{"nctId":"NCT03554447","phase":"NA","title":"Role of Pentoxifylline as an Adjuvant Therapy for Adult Patients With Major Depressive Disorder","status":"COMPLETED","sponsor":"Mahmoud Samy Abdallah","startDate":"2015-04-20","conditions":"Major Depressive Disorder","enrollment":80},{"nctId":"NCT00962039","phase":"PHASE2, PHASE3","title":"Anxiety and Recurrent Abdominal Pain in Children","status":"COMPLETED","sponsor":"John V. Campo, M.D.","startDate":"2004-07","conditions":"Abdominal Pain, Anxiety","enrollment":81}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":787,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Placebo & Citalopram","genericName":"Placebo & Citalopram","companyName":"University of Colorado, Denver","companyId":"university-of-colorado-denver","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Citalopram is a selective serotonin reuptake inhibitor (SSRI) that increases serotonin availability in the brain by blocking its reuptake at the presynaptic neuron. Used for Major depressive disorder, Generalized anxiety disorder, Panic disorder.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}